182 related articles for article (PubMed ID: 19435788)
21. P504S immunohistochemical detection in 405 prostatic specimens including 376 18-gauge needle biopsies.
Beach R; Gown AM; De Peralta-Venturina MN; Folpe AL; Yaziji H; Salles PG; Grignon DJ; Fanger GR; Amin MB
Am J Surg Pathol; 2002 Dec; 26(12):1588-96. PubMed ID: 12459625
[TBL] [Abstract][Full Text] [Related]
22. A retrospective study of high mobility group protein I(Y) as progression marker for prostate cancer determined by in situ hybridization.
Tamimi Y; van der Poel HG; Karthaus HF; Debruyne FM; Schalken JA
Br J Cancer; 1996 Aug; 74(4):573-8. PubMed ID: 8761372
[TBL] [Abstract][Full Text] [Related]
23. Protein expression of p53, bcl-2, and KI-67 (MIB-1) as prognostic biomarkers in patients with surgically treated, clinically localized prostate cancer.
Moul JW; Bettencourt MC; Sesterhenn IA; Mostofi FK; McLeod DG; Srivastava S; Bauer JJ
Surgery; 1996 Aug; 120(2):159-66; discussion 166-7. PubMed ID: 8751578
[TBL] [Abstract][Full Text] [Related]
24. SND1 facilitates the invasion and migration of cervical cancer cells by Smurf1-mediated degradation of FOXA2.
Zhan F; Zhong Y; Qin Y; Li L; Wu W; Yao M
Exp Cell Res; 2020 Mar; 388(1):111809. PubMed ID: 31891682
[TBL] [Abstract][Full Text] [Related]
25. Insulin-like growth factor (IGF)-I, IGF-II and IGF type I receptor (IGFR-I) expression in prostatic cancer.
Cardillo MR; Monti S; Di Silverio F; Gentile V; Sciarra F; Toscano V
Anticancer Res; 2003; 23(5A):3825-35. PubMed ID: 14666684
[TBL] [Abstract][Full Text] [Related]
26. SND1 expression in breast cancer tumors is associated with poor prognosis.
Gu X; Xue J; Ai L; Sun L; Zhu X; Wang Y; Liu C
Ann N Y Acad Sci; 2018 Dec; 1433(1):53-60. PubMed ID: 30216461
[TBL] [Abstract][Full Text] [Related]
27. Correlated overexpression of metadherin and SND1 in glioma cells.
Tong L; Wang C; Hu X; Pang B; Yang Z; He Z; He M; Wei L; Chu M
Biol Chem; 2016 Jan; 397(1):57-65. PubMed ID: 26351803
[TBL] [Abstract][Full Text] [Related]
28. [Expression of nucleostemin in prostate cancer tissues and its clinical significance].
Liu RL; Xu Y; Zhang ZH; Wang M; Sun JT; Qi SY; Zhang Y; Li SZ
Zhonghua Nan Ke Xue; 2008 May; 14(5):418-22. PubMed ID: 18572860
[TBL] [Abstract][Full Text] [Related]
29. Alpha-Methylacyl-CoA racemase: a novel tumor marker over-expressed in several human cancers and their precursor lesions.
Zhou M; Chinnaiyan AM; Kleer CG; Lucas PC; Rubin MA
Am J Surg Pathol; 2002 Jul; 26(7):926-31. PubMed ID: 12131161
[TBL] [Abstract][Full Text] [Related]
30. The prostate-specific G-protein coupled receptors PSGR and PSGR2 are prostate cancer biomarkers that are complementary to alpha-methylacyl-CoA racemase.
Wang J; Weng J; Cai Y; Penland R; Liu M; Ittmann M
Prostate; 2006 Jun; 66(8):847-57. PubMed ID: 16491480
[TBL] [Abstract][Full Text] [Related]
31. SND1 acts as an anti-apoptotic factor via regulating the expression of lncRNA UCA1 in hepatocellular carcinoma.
Cui X; Zhao C; Yao X; Qian B; Su C; Ren Y; Yao Z; Gao X; Yang J
RNA Biol; 2018; 15(10):1364-1375. PubMed ID: 30321081
[TBL] [Abstract][Full Text] [Related]
32. Expression patterns of candidate susceptibility genes HNF1β and CtBP2 in prostate cancer: association with tumor progression.
Debiais-Delpech C; Godet J; Pedretti N; Bernard FX; Irani J; Cathelineau X; Cussenot O; Fromont G
Urol Oncol; 2014 May; 32(4):426-32. PubMed ID: 24332637
[TBL] [Abstract][Full Text] [Related]
33. mRNA and micro-RNA expression analysis in laser-capture microdissected prostate biopsies: valuable tool for risk assessment and prevention trials.
Nonn L; Vaishnav A; Gallagher L; Gann PH
Exp Mol Pathol; 2010 Feb; 88(1):45-51. PubMed ID: 19874819
[TBL] [Abstract][Full Text] [Related]
34. Molecular markers in prostate cancer: the role in preoperative staging.
Moul JW; Merseburger AS; Srivastava S
Clin Prostate Cancer; 2002 Jun; 1(1):42-50. PubMed ID: 15046712
[TBL] [Abstract][Full Text] [Related]
35. Posttranscriptional Inhibition of Protein Tyrosine Phosphatase Nonreceptor Type 23 by Staphylococcal Nuclease and Tudor Domain Containing 1: Implications for Hepatocellular Carcinoma.
Jariwala N; Mendoza RG; Garcia D; Lai Z; Subler MA; Windle JJ; Mukhopadhyay ND; Fisher PB; Chen Y; Sarkar D
Hepatol Commun; 2019 Sep; 3(9):1258-1270. PubMed ID: 31497746
[TBL] [Abstract][Full Text] [Related]
36. Group IIA phospholipase A as a prognostic marker in prostate cancer: relevance to clinicopathological variables and disease-specific mortality.
Mirtti T; Laine VJ; Hiekkanen H; Hurme S; Rowe O; Nevalainen TJ; Kallajoki M; Alanen K
APMIS; 2009 Mar; 117(3):151-61. PubMed ID: 19245588
[TBL] [Abstract][Full Text] [Related]
37. Expression profile of prostate-specific antigen messenger RNA assessed by in situ hybridization is a novel prognostic marker for patients with untreated prostate cancer.
Tsurusaki T; Koji T; Sakai H; Kanetake H; Saito Y
Clin Cancer Res; 1998 Sep; 4(9):2187-94. PubMed ID: 9748138
[TBL] [Abstract][Full Text] [Related]
38. Androgen receptor coactivators lysine-specific histone demethylase 1 and four and a half LIM domain protein 2 predict risk of prostate cancer recurrence.
Kahl P; Gullotti L; Heukamp LC; Wolf S; Friedrichs N; Vorreuther R; Solleder G; Bastian PJ; Ellinger J; Metzger E; Schüle R; Buettner R
Cancer Res; 2006 Dec; 66(23):11341-7. PubMed ID: 17145880
[TBL] [Abstract][Full Text] [Related]
39. Abhydrolase domain containing 2, an androgen target gene, promotes prostate cancer cell proliferation and migration.
Obinata D; Takada S; Takayama K; Urano T; Ito A; Ashikari D; Fujiwara K; Yamada Y; Murata T; Kumagai J; Fujimura T; Ikeda K; Horie-Inoue K; Homma Y; Takahashi S; Inoue S
Eur J Cancer; 2016 Apr; 57():39-49. PubMed ID: 26854828
[TBL] [Abstract][Full Text] [Related]
40. The novel chromatin architectural regulator SND1 promotes glioma proliferation and invasion and predicts the prognosis of patients.
Yu L; Xu J; Liu J; Zhang H; Sun C; Wang Q; Shi C; Zhou X; Hua D; Luo W; Bian X; Yu S
Neuro Oncol; 2019 Jun; 21(6):742-754. PubMed ID: 30753603
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
